#8378. Hematopoietic Stem Cell Transplant for Sickle Cell Disease: PATIENT SELEction and Timing Based on Sickle Cell-Related Multiple Chronic Conditions

July 2026publication date
Proposal available till 05-06-2025
4 total number of authors per manuscript6020 $

The title of the journal is available only for the authors who have already paid for
Journal’s subject area:
Medicine (all);
Places in the authors’ list:
place 1place 2place 3place 4
FreeFreeBookedSold out
2510 $1340 $1170 $1000 $
Contract №8378.1 Contract №8378.2 Contract №8378.3 №8378.4
1 place - free (for sale)
2 place - free (for sale)
3 place - booked till 11-05-2025
4 place - sold out (contract 7009)

Abstract:
Hematopoietic stem cell transplant (HSCT) is the only cure for patients with sickle cell disease (SCD). Although most SCD patients experience progressive end-organ damage and shortened lifespans, not all patients follow the same disease course, tempo, or outcome. Therefore, the dilemma facing physicians is weighing the selection of patients and timing for the procedure against donor type and transplant-related mortality and morbidity that go up with increasing age. On the other hand, the dilemma facing the patients and families is how acceptable HSCT that carries some mortality risks to them. We have analyzed the chronic conditions due to SCD in 449 patients to determine whether SCD-related multiple chronic conditions (MCC) can be risk-stratified to identify the group of patients predicted to not only have shortened lifespans but also functional limitation and poor quality of life so that these at-risk patients can be offered HSCT early and before MCC develops.
Keywords:
allogeneic stem cell transplant; patient selection; sickle cell disease; timing of transplant

Contacts :
0